StockpollyBeta
Get App
Popularity #3,667
COYA · NASDAQ · Biotechnology

Coya Therapeutics (COYA)

Develops Treg-focused therapies for neurodegenerative and immune-mediated diseases.

$5.38
After hours+0.07 (+1.32%)
At close$5.31(+7.27%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue060300004400
Cost of revenue223522500000
Gross profit−24−3−1−2−2−504400
2322223751087
Research & development22352253,6633745
22222232,9083342
General & administrative22222232,9083342
Other expenses−2−2−3−5−2−2−5−6,5650000
Operating income−42−5−3−4−4−8−6−2−6−8−7
000000000000
Other non-operating income000000000000
Income before tax−32−5−3−4−4−7−6−2−6−7−7
Income tax expense01000−1000000
Net income from continuing operations−31−5−3−4−3−7−6−2−6−7−7
Net income−31−5−3−4−3−7−6−2−6−7−7
EPS, basic−$0.34$0.12−$0.35−$0.19−$0.26−$0.18−$0.44−$0.36−$0.13−$0.34−$0.32−$0.28
EPS, diluted−$0.34$0.12−$0.35−$0.19−$0.26−$0.18−$0.44−$0.36−$0.13−$0.34−$0.32−$0.28
Weighted average shares, basic101014151516171717172323
Weighted average shares, diluted101014151516171717172323
EBITDA−42−5−3−4−4−7−6−2−6−8−7
Depreciation & amortization000000000000
EBIT−42−5−3−4−4−7−6−2−6−8−7